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Abstract
Many of the neutralising antibodies, isolated to date, display limited activities against the globally most prevalent HIV-1
subtypes A and C. Therefore, those subtypes are considered to be an important target for antibody-based therapy. Variable
domains of llama heavy chain antibodies (VHH) have some superior properties compared with classical antibodies.
Therefore we describe the application of trimeric forms of envelope proteins (Env), derived from HIV-1 of subtype A and B/C,
for a prolonged immunization of two llamas. A panel of VHH, which interfere with CD4 binding to HIV-1 Env were selected
with use of panning. The results of binding and competition assays to various Env, including a variant with a stabilized CD4-
binding state (gp120Ds2), cross-competition experiments, maturation analysis and neutralisation assays, enabled us to
classify the selected VHH into three groups. The VHH of group I were efficient mainly against viruses of subtype A, C and B9/
C. The VHH of group II resemble the broadly neutralising antibody (bnmAb) b12, neutralizing mainly subtype B and C
viruses, however some had a broader neutralisation profile. A representative of the third group, 2E7, had an even higher
neutralization breadth, neutralizing 21 out of the 26 tested strains belonging to the A, A/G, B, B/C and C subtypes. To
evaluate the contribution of certain amino acids to the potency of the VHH a small set of the mutants were constructed.
Surprisingly this yielded one mutant with slightly improved neutralisation potency against 92UG37.A9 (subtype A) and
96ZM651.02 (subtype C). These findings and the well-known stability of VHH indicate the potential application of these VHH
as anti-HIV-1 microbicides.
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Introduction
Neutralising antibodies against the human immunodeficiency
virus type 1 (HIV-1) are powerful tools not only for understanding
the virus structure [1–4] and the mechanism of cellular entry [5,6],
but also for passive immunization [7–9]. Many monoclonal
antibodies specific for HIV-1 envelope proteins, gp120 and
gp41, have been isolated both from immunised animals and
infected individuals. However, only a few of these are broadly
neutralising. These rare antibodies, including b12, 2G12, 2F5,
4E10 and65 [10,11] have all been derived from HIV-1 subtype B
infected patients and, besides 4E10, display limited activity against
the globally most prevalent subtype C HIV-1 [12–15]. More
recently other promising broadly neutralizing monoclonal anti-
bodies (bnmAbs), notably PG16, PG9 [16,17], HJ16 [18],
VRC01-03 [19] and 3BNC60 and 117 [20] have been described.
Many of these bnmAbs recognize the CD4bs and the sometimes
relatively small differences in the interaction area, derived from X-
ray data, resulted in quite different neutralization potencies
[19,21]. Isolation and characterisation of novel bnmAbs, with
specific attention to non-subtype B viruses, may aid the design and
development of a vaccine capable of inducing a broadly protective
antibody immune response. Additionally, such antibodies might be
developed as specific entry inhibitors for inclusion in HIV-1
microbicides [22].
Llamas, and other Camelidae, possess conventional antibodies
and heavy chain antibodies. The latter are devoid of light chains
[23] and the Variable domain of the Heavy chain of the Heavy
chain antibodies (VHH) is therefore solely responsible for antigen
recognition. The specificities and affinities of VHH are compa-
rable to those of IgGs even though the size of a VHH is only
approximately 15 kDa., compared to the 150 kDa. of IgG. On
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(CDR3) [24–26], a feature that might facilitate binding into deeper
cavities on the antigen surface. Grooves and cavities play a crucial
role in multiple biological activities as these often form the specific
interaction site between two molecules [25]. Fitting into the CD4bs
is thought to be important for potent neutralisation of HIV-1 via
binding to the envelope spike [16,27]. Moreover the small size of
VHH may be an important property to inhibit transmission of HIV
in the small viral synapsis [28]. The high stability [24,29–32] and
the often excellent expression yield of VHH in microbial
fermentations [33,34] make VHH realistic candidates for the
development of microbicides to protect against HIV infections.
We have shown that neutralising VHH can be raised in llamas
immunized with gp120 of HIV-1CN54 [35]. Although the selected
VHH exhibited neutralising effects against HIV-1 primary isolates
of subtype B and to a lesser extent subtypes C, they did not
neutralise HIV-1 subtypes A, A/G and D.
In the present study, we immunised two llamas with a mixture
of two different antigens, gp140CN54 (subtype B/C) and
gp140UG37 (subtype A) to promote the development of broadly
reactive VHH. Here we describe the selection of VHH from
immune phage display libraries by competition with sCD4, which
resulted in the isolation of a number of VHH that not only
competed with broadly neutralising anti-CD4 binding site
antibody (b12) for binding to HIV-1 envelope proteins, but also
revealed neutralising activities against a panel of primary HIV-1
including A, B and C subtypes. We classified the neutralising
VHH into three groups based on sequence analysis and alignment
against the llama’s germline V-, D- and J-genes, binding and
competition experiments, and neutralization assays. These data
demonstrate the diversity of epitopes recognized by these VHH
and suggest various mechanisms of HIV-1 entrance inhibitions.
Materials and Methods
Ethics statement
The prolonged Llama immunizations were approved and
performed according to the guidelines of Utrecht University
Animal Ethical Committee (approval ID: 2007.III.01.013).
Proteins
Soluble CD4 (sCD4) was purchased from R&D systems (cat 514-
CD/CF), Concanavalin A (ConA; cat. C2010) and biotinylated
ConA (cat. C2272) were purchased from Sigma-Aldrich Chemie BV,
The Netherlands. Recombinant HIV-1 envelope proteins gp140CN54
(0699), gp120IIIB (0607) and gp120CN54 (6015) used for binding and
competition assays, and the anti-CD4bs monoclonal antibody (mAb)
b12 (3065) were obtained from the Centre for AIDS Reagents,
NIBSC HPA UK, supported by the EC FP6/7 Europrise Network of
Excellence, and NGIN consortia and the Bill and Melinda Gates
GHRC-CAVD Project and were donated by Polymun, Immuno-
diagnostics,ImmuneTerchnologyandDrsDPBurtonandPParren,
respectively. Envelope proteins gp140UG37 and gp140CN54 used for
immunization were kindly provided by Dr S. Jeffs, Wright-Fleming
Institute, Division of Medicine, Imperial College London, London,
UK. Envelope proteins gp120YU2 and its modified variant gp120Ds2
were kindly provided by Dr. P. Kwong, Vaccine Research Center,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, USA. The anti llama IgG3 mAb
8E1 was kindly provided by BAC BV, Naarden.
Viruses
HIV-1 IIIB (0101) and MN (0102) were obtained from the
Centre for AIDS Reagents, NIBSC HPA UK, supported by the
EC FP6/7 Europrise Network of Excellence, and NGIN consortia
and the Bill and Melinda Gates GHRC-CAVD Project and was
donated by Drs R Gallo & M Popovic and propagated in H9 and
C8166 cells, respectively. Virus stocks of HIV-1 envelopes
pseudotyped with the pSG3Denv vector and replication-compe-
tent HIV-1 molecular clones were produced by transfection of
293T cells [36]. The subtype B (THRO4156.18, TRJO4551.58,
6535.3) and C (Du156.12, Du422.1, ZM197M.PB7,
ZM214M.PL15, ZM233M.PB6, ZM109F.PB4, ZM135M.PL10a,
CAP45.2.00.G3) HIV-1 Reference Panels of Env. Clones [36]
were obtained through the AIDS Research and Reference
Reagent Program (ARRRP), Division of AIDS, NIAID, NIH
(USA). HIV-1 subtype CRF02_AG (T257-71, T266-60, T278-50
and T33-7) gp160 clones, subtype CRF07_BC gp160 clones
(CH038.12, CH064.20, CH091.9, CH110.2 and CH181.12),
96ZM651.02 and MS208.A1 p160 clones were kindly provided by
Dr D. Montefiori (Duke University Medical Centre, Durham,
USA) through the Comprehensive Antibody Vaccine Immune
Monitoring Consortium (CA-VIMC) as part of the Collaboration
for AIDS Vaccine Discovery (CAVD). Virus 92UG037.A9 is a
gp120 clone of the primary isolate 92UG37 [37] cloned into the
pHXB2Denv vector [38].
Binding sCD4 and b12 antibodies to gp140 and 120
molecules
To determine the functionality of envelope molecules, their
interactions with sCD4 and b12 were tested. MaxiSorp microtitre
plates (cat 442404, Nunc GmbH & Co. KG, Germany) were
directly coated with envelope proteins serially diluted in PBS and
incubated at 4uC overnight. After treatment with 4% skimmed milk
powder (Marvel) in PBS (4% MPBS) for 1 h at room temperature
(RT), 50 mL sCD4 [3 mg/mL] or 50 mL b12 [100 ng/mL] in 1%
MBPS was added and incubated for an additional 1 h at RT,
shaking. Soluble CD4 was detected with L120 (mouse anti CD4,
1:10,000 in 1% MPBS; NIBSC) and b12 was detected with rabbit
anti-human IgG (1:10,000 in 1% MPBS; DAKO). Finally,
peroxidase-conjugated donkey anti-mouse or donkey anti-rabbit
IgG (1:5,000 in 1% MPBS; Jackson Immunoresearch, West Grove,
PA, USA) were added. Plates were washed three times with PBST
(PBS supplemented with 0.05% Tween 20) between each step. The
complexes were visualised by o-Phenylenediamine (OPD) according
to method described by Verheesen et al. [39].
Immunisation of Lama glama with gp140UG37 and
gp140CN54
Two Lama glama were injected intramuscularly with mixture of
gp140CN54, and gp140UG37,5 0mg of each protein in commer-
cially available Stimune adjuvant (CEDI Diagnostics, Lelystad,
The Netherlands). First boosting was given on day 7, with the
same immunogens doses as the first injection. The following
booster injections were given on days 14, 21, 28, 35 and 113 with
mixture containing 25 mg of each gp140. Ten millilitres blood
samples were collected at days 0 (before injection), 21 and 113. To
construct immune libraries, 150 ml blood samples were collected
at day 43 and 122.
To assess the llamas’ immune response, MaxiSorp microtitre
plates were coated with 50 mL gp140CN54, gp140UG37 or gp120IIIB
[5 mg/mL] as described above. After blocking with 200 mL4 %
MPBS serial dilutions of pre-immune and immune sera were
incubated for 1 h. Detection of bound llama single chain
antibodies was performed by incubation with the IgG3 specific
mAb 8E1 [40] followed and peroxidase-conjugated donkey anti-
mouse all in 50 mL. Complexes were detected as described above.
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To construct immune libraries, 150 ml blood samples were
collected at 122 day, and peripheral blood lymphocytes (PBLs)
were purified by Leucosep (cat 227290, Greiner Bio-One BV, The
Netherlands). Total RNA was extracted from PBLs as described
by Chomczynski et al. [41] and random primed complementary
DNA (cDNA) was synthesised using SuperScript
TM III First-
Strand Synthesis System for RT-PCR (Invitrogen, cat. 18080-
051). After purification of the cDNA with QIAquick PCR
Purification Kit (Qiagen, cat 28106), the cDNA was used as
template for PCR using the combination of the leader and CH2
based primers [39] which resulted in an amplification of the
conventional and heavy-chain IgG repertoire gene fragments. Due
to the lack of CH1 region in heavy-chain antibodies, the amplified
gene fragments of conventional and heavy-chain antibodies were
separated on agarose gel. Subsequently, a SfiI restriction site was
introduced upstream of FR1 in a nested PCR using the gel
purified heavy chain amplicon as template. Since a BstEII
restriction site naturally occurs in 90% of the FR4 of llama
heavy-chain antibodies genes [42] the repertoire of PCR-amplified
genes was cut with BstEII and SfiI and the resulting 300–400 bp
fragments were purified from agarose gel. Finally cDNA fragments
were ligated into a phagemid vector for display on filamentous
bacteriophage [43] and electroporated in E. coli TG1 (K12, _(lac-
pro), supE, thi, hsdD5/F9traD36, proA+B+, lacIq, lacZ_M15).
The rescue with helper phage VCS-M13 and polyethylene
glycol precipitation was performed as described previously [44].
Phage stock containing 5610
11 pfu/ml was prepared and used for
subsequent biopanning.
Selection of clones competing with sCD4 for binding to
gp140
To select phages that specifically bound to CD4 binding site of
gp140 the modified competitive elution method [35,45,46] using
sCD4 as selective eluant was applied. Wells of MaxiSorp
microtitre plates were coated with 100 mLg p 1 4 0 CN54 [2.5 or
0.5 mg/mL] in PBS overnight at 4uC. Blocking was performed
with 2% MPBS. After washing the plate with PBS, 5610
9 phages,
which were preincubated in blocking buffer for 30 min at RT,
were added to the wells and incubated for 2 hours at RT. Next,
the coated wells were extensively washed with PBS. Subsequently,
100 mLs C D 4[ 3 0 mg/mL] or 100 mL triethylamine (TEA)
100 mM were added and the plates incubated for 30 min at
RT. The eluates were removed, the TEA eluted phage was
neutralised with half volume of 1 M Tris pH 7.5, and
subsequently 10-fold serial dilutions in PBS were prepared. Ten
microlitres of each dilution was used for infection of 190 mL log-
phase E. coli TG1. After infection at 37uC for 30 min without
shaking, 5 mL of bacterial suspensions were spotted on LB agar
plates supplemented with 100 mg/mL ampicillin and 2% glucose
(LB/Amp
100/Glu
2%) to determine the enrichment of the first
round. Moreover, 75 mmL of eluate was used for infection 0.5 mL
log-phase E. coli TG1 to rescue phages [44], and were
subsequently applied for second round of selection. The
conditions of the following selection round were identical to the
first one.
Screening ELISA
At the end of the second round, 100 mL serially diluted infected
E. coli TG1 were plated on LB/Amp
100/Glu
2% agar plates and
single colonies were picked and grown in 26YT broth containing
100 mg/mL ampicillin and 2% glucose (26 YT/Amp
100/Glu
2%)
in 96-well microtitre plate format.
Expression of the VHH from single clones was performed in 96
deep-well plates (cat.AB-0932, Westburg B.V, The Netherlands)
according to the modified method described by Marks et al. [44].
Briefly, 1 mL of 26 YT/Amp
100/Glu
0.1% broth was inoculated
with 10 mL overnight culture and grown with shaking at 37uC
until OD600=1 was reached. Expression of the protein was
induced by adding IPTG (final concentration of 1 mM) and the
cultures were grown for additional 4 hours with shaking at 37uC.
After harvesting bacteria by centrifugation for 15 min at 45666g
and freezing pellets overnight at 220uC, bacteria were resus-
pended in 100 mL PBS and shaken for 2 h at 4uC. Next,
spheroplasts were harvested by centrifugation for 15 min 45666g
at 4uC and supernatants (i.e. periplasmic fractions) containing
VHH were taken for screening assays.
Periplasmic fractions were screened for their ability to interfere
with binding of monoclonal antibodies (mAb) b12 to gp140CN54 by
direct competitive enzyme-linked immunosorbent assay (ELISA).
This approach was chosen because of the weak interaction
between gp140CN54 and sCD4 in our ELISA setup that prevented
screening of individual clones for competition with sCD4. For this
purpose, wells of MaxiSorp microtitre plates were coated with
50 mL b12 [2 mg/mL] in PBS overnight at 4uC. Next, the b12-
coated wells were blocked with 4% MPBS for 1 hour. In the
meantime, mixtures of 5-fold diluted periplasmic fractions and
1 mg/mL gp140CN54 (final concentration) in 1% MPBS were
prepared and incubated for 1 hour at room temperature. Then
50 mL of the mixtures were transferred into blocked, b12-coated
wells and incubated for an additional 1 hour. To detect bound,
non-inhibited gp140CN54 biotinylated concanavalin A (ConA) was
used at concentration 2 mg/mL in 1% MPBS followed by addition
of streptavidin-HRP conjugate. Complexes were detected as
described above. Positive clones, which gave a low signal in the
b12 competition assay, were selected and one-way sequencing was
performed by application M13Rev primer [39] (ServiceXS,
Leiden, The Netherlands). For further characterisation, VHH
genes were recloned into the E.coli production vector and after
expression the VHH were purified by means of immobilised metal
affinity chromatography (IMAC) as it has been described by
Verheesen et al. [47].
Characterisation of selected VHH
Sequence comparisons. To analyse the maturation and to
classify the selected VHH, we grouped them according to the use
of the germline V, D and J segments using a database with twenty
three different V gene segments of Lama glama; seven D gene
segments of Lama pacos; and five J gene segments of Lama glama [48]
supplemented with two missing J gene segments of Lama pacos [49].
To analyse the sequences, WHAT IF’s [50] implementation of
combined DNA codon/amino acid alignments of all germ line
genes against selected VHH sequences was performed. The D
gene segments were translated in three readings frames and the
best fitting D-segment was used to analyse maturation of CDR3.
The DNA/amino acid sequence format dictates that the triplet
and the corresponding amino acid (so each codon is followed by its
cognate amino acid e.g. cagQgtgVcagQ) remained associated in-
phase in subsequent alignment procedures. The aligned DNA/
amino acid sequences allowed fitting short sequences, such as D
gene segments, and differentiate between silent and functional
mutations.
VHH binding to different envelope proteins. To test
binding of purified VHH to various envelope proteins, gp120IIIB
(clade B), gp140CN54 (its gp120 is representing clade C),
gp140UG37 (clade A) gp120YU2 (clade B) and its modified variant
gp120Ds2 were directly coated on Nunc MaxiSorp plates in 50 mL
Broadly Neutralizing VHH against HIV-1
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with 4% MPBS as described above, VHH diluted in 1% MPBS
were allowed to interact with the envelope protein. Subsequently,
bound VHH were detected with mouse anti-C-Myc (9E10)
antibodies, which recognised C-terminal Myc tag incorporated
in VHH, and the detection was followed by incubation with
donkey anti-mouse – HRP conjugate. The signals were quantified
by colorimetric assay described above. The experiments were
performed in triplicates. Binding activities of 2E7 variants were
tested in a similar manner, with exception of coating wells with
50 mL[ 4mg/mL] of envelope proteins and detection of VHH with
rabbit anti-llama VHH serum [51] followed by goat anti-rabbit
HRP conjugate.
Competition assays. To test possibility of epitope
overlapping of selected VHH and b12 monoclonal antibodies we
applied the method described by Kuroki [36,52]. Microtitre plates
were coated with 50 mL, [2 mg/mL] of b12. Equal volumes of
2 mg/mL gp120IIIB, gp140CN54 or gp140UG37 and serially diluted
VHH were preincubated, and subsequently added to the mAb b12
coated and blocked wells. After 1 hour, bound HIV-1 envelope
proteins were detected by ConA as described above. The
experiments were performed in triplicates. The absorbance at
490 nm (A490) of each tested sample was expressed as a percentage
of positivity (PP), calculated by the following equation: PP=100 *
((A490sample2A490min)/(A490max2A490min), where A490min is a A490
of sample without VHH and without envelope protein; and
A490max is A490 of samples without VHH for particular envelope
protein and finally A490sample is the signal of sample with both the
VHH and the envelope protein [53][54]. To determine the
descriptive measures such as mean (X) and standard deviation
(S.D.), the results (expressed as PP) were processed with SPSS
version 16.0 for Windows.
Cross-competition assays between selected VHH were per-
formed in a similar manner. The only exceptions were: coating
plates with 50 mL[ 3mg/mL] of VHH and preincubation of equal
volumes of 50 mg/mL VHH with 5 mg/mL gp140CN54 or
gp140UG37. As a negative control we used anti EGFR VHH
[42]. The experiments were performed in duplicates. PP was
calculated as described above with the difference that A490 min is a
A490 of sample, where the same VHH were used in solution as the
immobilized VHH; and A490max is A490 of samples, where anti
EGFR VHH were applied as the VHH in solution for the
particular immobilized VHH.
HIV neutralisation assay
The HIV-1 neutralising activities of the VHH were assessed in
the TZM-bl cell based assay, as described previously [55] Briefly,
3-fold serial dilutions of purified VHH starting from 50 mg/mL
were performed in duplicate in 10% (v/v) fetal calf serum (FCS)
supplemented DMEM growth medium (Invitrogen, Paisley, UK).
200 TCID50 of virus was then added to each well and the plates
were incubated for 1 hour at 37uC. TZM-bl cells were
subsequently added (1610
4 cells/well) in growth medium
supplemented with DEAE-dextran (Sigma-Aldrich, St Louis,
MO, USA) at a final concentration of 15 mg/mL. Assay controls
included replicate wells of TZM-bl cells alone (background
control), and TZM-bl cells with virus assayed (virus control). No
virus inactivation was observed with a negative control VHH.
Following 48 hours incubation at 37uC, all 100 mL of the assay
medium was removed and 100 mL of Bright-Glo luciferase reagent
(Promega, Madison, WI, USA) was added to each well. The cells
were allowed to lyse for at least 2 minutes, and the luminescence
was then measured using a luminometer. The 50% inhibitory
concentration (IC50) titres were calculated as the VHH concen-
tration that achieved a 50% reduction in relative luminescence
units (RLU) compared to the virus control RLU, after subtraction
of the background control RLU from both values. The
calculations were performed using the XLFit4 software (ID
Business Solutions, Guildford, UK).
Construction, expression and purification of VHH variants
Alanine scan was performed on residues N27, V29 (CDR1);
D32 (FW2) and Y98, Y99, G100, R100b, Y100c, D101, Y102
(CDR3) of 2E7 by site-directed mutagenesis (SDM) with
application of the QuikChangeH Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) according to instructions provided
by manufacturer. In addition, the same method was applied for
introduction of back-to-germline-mutations in CDR1: N27S,
V29F, and in FW2: D32N. The introduced mutations were
verified by plasmid sequencing (ServiceXS, Leiden, The Nether-
lands). Expression and purification of mutated 2E7 variants were
performed as previously described by Verheesen et al. [47].
Results
Immune response and library construction
To obtain VHH specific for HIV-1 envelope proteins, two Lama
glama were immunized with a cocktail of gp140CN54 (subtype, B/
C, but the gp120 is representing subtype C) and gp140UG37
(subtype A). The induction of a humoral immune response was
followed by testing sera of the animals before and after
immunization by ELISA. Immunizations resulted in the induction
of a specific heavy chain antibody response towards both
immunogens (Fig. 1.). The titer of anti-gp140UG37 antibodies in
immune sera was slightly higher than of anti-gp140CN54.I n
addition, the immune sera were also reactive with gp120IIIB
(subtype B). These data clearly demonstrate the successful
induction of a humoral immune response towards the HIV-1
envelope proteins.
Since the immune response was good, library construction was
continued. The synthesis of the VHH repertoires resulted in two
libraries: llama 8 and llama 9, of approximately 10
7 transformants
each.
VHH selection by competitive elution with sCD4
The specific competitive elution method required binding of
sCD4 to gp140CN54. Therefore we tested how well the envelope
protein was recognised by sCD4 in ELISA. As shown in
supporting figure 1, sCD4 bound to gp140UG37 in a dose
dependant manner (0.37–10 mg/mL). However, binding of
sCD4 to gp140CN54 was only detectable at high concentrations
(10 mg/mL) of the envelope protein. Therefore a high concentra-
tion of sCD4 was used as elution method during phage display, to
ensure that all CD4 binding sites of the coated envelope proteins
were saturated, thus preventing rebinding of phages displaying
VHH that recognize this site.
Two rounds of selection were performed. In the first round,
1.5610
6 phages were non-specifically eluted by TEA from
gp140CN54 coated at 2.5 mg/mL and 100 fold lower outputs were
obtained from 0.5 mg/mL. Approximately 15 fold lower number
of phages was eluted with sCD4 from 2.5 mg/mL coat and
approximately the same number of phages were found for the
0.5 mg/mL coated wells as compared to TEA elution. For the
second round, the rescued phages from 2.5 mg/mL gp140CN54
eluted with sCD4 were used and the selection procedure was
repeated. Surprisingly no difference was observed between
number of phages eluted with sCD4 and with irrelevant protein
BSA for llama 8 library. However, in case of llama 9 library, ten
Broadly Neutralizing VHH against HIV-1
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sCD4 than with BSA, thereby indicating a successful competitive
elution with sCD4. Out of 280 single clones picked from the
selection approximately 87% of the clones were able to bind
specifically to gp140CN54.
In order to narrow down the investigation to clones that
potentially were able to bind to CD4bs we performed a
competition assay with b12. The setup of the sCD4 competition
ELISA on gp140CN54, applied for selection of VHH with the
specific competitive elution method, could not be used for
screening purpose, because a too high concentration of sCD4
was required (10 mg/ml) to get a signal. Therefore we tested the
ability of b12 to bind to the envelope proteins, since the b12
binding epitope overlaps partially with CD4bs [2]. In contrast to
sCD4 binding, b12 binding to gp140UG37 was observed at
envelope protein concentrations above 3.3 mg/mL (Fig. S1). For
gp140CN54, a decent signal was already observed at concentrations
as low as 1 mg/mL. Therefore, this setup was used as the
competition ELISA for screening purpose. Approximately 11%
from the 280 clones were able to compete with b12 (data not
shown) and therefore selected for further VHH characterisation.
Sequences analysis
The 30 competing clones were sequenced and based on
deduced amino acids sequence 17 unique VHH were found,
which were divided into seven families based on the DNA/amino
acid alignment with the 23 V, the 7 D and the 7 J genes [48,49]
(Fig. 2). The maturation analysis revealed that four germline V
gene segments were used to encode the VHH identified in the
mAb b12 competition assay. Eleven VHH were derived from Vd
gene, three VHH from Vg, two from the Vo gene and another one
from the Vm gene. Probably two different D genes have been used
in the group derived from Vd gene and on that basis two
subpopulations of VHH could be distinguished in this group.
Sequences of all selected VHH revealed that only J3 or J7 gene
segments contributed in the formation of the VHH CDR3 loops.
A notable feature of the selected VHH is a relatively long CDR3
loop in most of the selected VHH. This panel of VHH has an
average length of 16.4 residues compared to an average of 12.7 for
the human heavy chain CDR3 and 8.5 for mice [56].
Examination of amino acids sequences showed that besides strictly
conserved disulfide bridge (C22–C92) typical of the immunoglob-
ulin fold, an extra pair of cysteines is present in the sequences of
most of the newly selected VHH. The VHH originated from the
Vd gene have an extra cysteine at position 50, which forms an S-S
bridge with a cysteine at various positions in CDR3. This feature
has been previously observed by Vu et al. [26]. Noteworthy is the
fact that VHH 1B5 and 1H9, which derive from Vg gene segment,
contain a cysteine at position 52a in CDR2 and a second
additional cysteine at position 71 in FW3. Interestingly, both
cysteines were not present in the original germline sequence, and
were never seen before in our hands, nor in the antibody database
Fungen (fungen.wur.nl) or the protein data bank (www.wwpdb.
org). The introduction of this new location of a cysteine bridge
must be important for the function of these VHH. Evidence for
such maturation step is provided by 1E1, which is closely related to
1B5, but lacks the additional cysteines and is less potent than 1B5,
indicating that the S-S bridge is important for binding and
neutralization. This observation was confirmed by replacement of
both cysteines in 1B5 (data not shown).
Binding of selected VHH to envelope proteins
Purified VHH were tested in ELISA to characterise their ability
to recognise directly coated HIV-1 envelope proteins gp140CN54,
gp140UG37, gp120IIIB, gp120YU2 and its modified variant
gp120Ds2 (Table 1, Fig. S2). All selected VHH bound reasonable
well to both gp140CN54 and gp140UG37, with the exception of
2D4, which demonstrated limited binding to gp140CN54. VHH
1F10 and 1C2, as well as 1B5 and 1H9, which belong to two
different families, were the best binders to gp140CN54 and
gp140UG37 and reached half of maximal signal at concentrations
below 0.63 mg/mL (or 42 nM). Only VHH of the 1B5 family
(1B5, 1H9, 1E1) were able to bind to subtype B envelope proteins,
although less efficiently than to gp140CN54 and gp140UG37. VHH
1B5 and 1H9 reached half of maximum signal at a concentration
between 82 and 330 nM of all subtype B envelope proteins tested.
In contrast, 1E1 lacking the second S-S bridge present in the other
members of this family bound very weakly to gp120IIIB as well as
to gp120YU2, and binding to gp120Ds2 was not detectable. As a
comparison, previously selected VHH A12 [35] bound to
gp120IIIB as good as 1B5 and 1H9, but was unable to bind to
gp120Ds2 (data not shown). Furthermore, VHH A12 bound to
gp140UG37 very well but poorly to gp140CN54.
Competition assay between b12 and VHH
To assess whether the selected VHH bind to HIV-1 envelope
proteins in a way that they may interfere with CD4 binding, we
performed a competition assay with b12 (Table 2, Fig. S3). We
chose to work with the anti-CD4bs mAb instead of sCD4, because
of the poor sCD4 binding to gp140CN54 shown previously (Fig.
S1). Note that the epitope of b12 does overlap with the CD4bs but
it is not exactly the same, so competition with b12 does not
Figure 1. Heavy chain antibody response of llama 8 and 9.
Heavy chain antibody response in llama 8 (A) and llama 9 (B) to
gp140UG37 (%), gp140CN54 (&), gp120IIIB (&) at indicated days
following initial immunisation. Sera from llamas were collected, diluted
1000 fold and tested by ELISA for the presence of specific IgG3 heavy
chain antibodies coated recombinant HIV-1 envelope proteins.
doi:10.1371/journal.pone.0033298.g001
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b12 was assessed by using gp120IIIB, gp140CN54 and gp140UG37,
as it is known that CD4 binding sites may differ between various
HIV-1 subtypes [2,57]. Our data show that all VHH inhibited
binding of b12 to gp140CN54 and VHH 1C2, 1B5, 1H9 and A12
prevented the binding of b12 to gp140CN54 at concentrations
lower than 30 nM.
Cross-competition assay
To further characterise the selected VHH, we tested whether
they compete with each other or if they can bind to envelope
proteins at the same time. For this purpose we applied the
competition assay described by Kuroki [52]. Since CD4bs and b12
epitopes differ in various HIV-1 envelope proteins [2,57], the
experiments were performed with both envelope proteins
Figure 2. Alignment of the VHH against the germline V, D and J segments. Amino acids sequences of HIV-1 envelope protein CD4bs specific
VHH aligned against Lama glama V and J germ line genes and D germ line genes of Lama pacos. The reading frame of the most likely D germline
genes are marked. Numbering of amino acid according to Kabat et al.. CDRs of VHH are redefined.
doi:10.1371/journal.pone.0033298.g002
Table 1. Summary of VHH binding to HIV-1 envelope
proteins.
HIV-1 envelope protein
VHH gp140UG37 gp140CN54 gp120IIIB gp120YU2 gp120Ds2
1C2 +++ +++ ---
1F10 +++ +++ --+
1E1 ++ +++ + + -
1B5 +++ +++ ++ ++ ++
1H9 +++ +++ ++ ++ ++
1E2 ++ ++ ---
2E7 ++ ++ + --
A12 +++ + +++ N.D. N.D.
The amount of VHH required to give half-maximal A490 was estimated from the
respective binding curves. +++ half-maximal binding at ,0.63 mg/mL; ++, 0.63–
10 mg/mL; +, .10 mg/mL; -, no binding was observed even at the highest
amount of VHH. N.D., not done.
doi:10.1371/journal.pone.0033298.t001
Table 2. Summary of VHH competition with mAb b12 for
binding to HIV-1 envelope proteins.
HIV-1 envelope protein
VHH gp140UG37 gp140CN54 gp120IIIB
1C2 +++ ++ -
1F10 ++ ++ -
1E1 ++ ++ +
1B5 ++ ++ ++
1H9 +++ ++ ++
1E2 ++ ++ -
2E7 ++ ++ +
A12 +++ ++ ++
The amount of VHH required to reduce the b12 signal by 50% of its maximum
was estimated from the respective competition curves. +++ ,0.44 mg/mL; ++
0.44–12 mg/mL; + .12 mg/mL; -,no competition was observed even at the
highest amount of VHH.
doi:10.1371/journal.pone.0033298.t002
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competition together with similarity between CDRs was taken as
evidence of overlapping epitopes. To define strength of compe-
tition we followed the rules described by Tzartos [58]. Although
slightly more marked cross-competition reactions were observed
for gp140CN54 than for gp140UG37, the general pattern of cross-
competition was similar for both envelope proteins. VHH 2E7
binding to its epitope was hampered by 1E2 and 1C12, and vice
versa. Noteworthy is the fact that all three VHH derive from
various V genes and differ in CDR3 sequences.
Based on those data and sequence and maturation data the
selected VHH were classified into three neutralising groups (I–III)
(Figure 3). Group III is composed of 2E7 VHH, which originate
from germline Vm gene. The other members of this grouphave been
selected by additional rescreening of library 9 (data not shown).
Neutralisation assay
Functional characterisation of the VHH was assessed in the
TZM-bl cell based neutralisation assay developed by Derdeyn et al.
[59], Wei et al. [60] and Li et al. [36]. The lowest VHH
concentration required to achieve 50% reduction of infectivity
(IC50) in comparison to a virus control was next determined against
a panel of 26 HIV-1 strains from clade A, B, C, A/G and B/C
origin. The results presented in the Table 3 show that VHH from
different groups have different neutralization profiles. In contrast to
the previously described VHH A12, D7 and C8 [35], as well as
mAb b12, which showed the most potent activity against HIV-1
subtype B, some of the newly selected VHH were active against
subtype C and B/C HIV-1. Overall, VHH 1B5 and 2E7 were the
most broadly neutralising VHH demonstrating inhibitory activity
against respectively 18 and 21 out of 26 viruses tested, predomi-
nantly tier 2 neutralization sensitivity class. VHH 1C2 and 1F10
were active against all subtype A, C and B/C viruses tested, but
were inactive against most of subtype B and A/G strains.
Effect of CDR1 and CDR3 mutations on 2E7 activity
As shown above, 2E7 VHH revealed the broadest cross-subtype
neutralisation activities, yet its neutralisation potency was lower
than b12. Therefore we were interested in determining the
influence of single amino acids substitutions in 2E7 VHH on
envelope protein binding and neutralisation potency as a start for
in vitro maturation. We were particularly interested in CDR1 and
CDR3 regions since they have been shown to be mainly involved
in interaction with antigen [61,62]. Surprisingly back-mutation to
germline residue on position 29 (V29F) seems to enhance binding
of the VHH to gp140CN54. The alanine scan showed lack of effect
of D32A on binding to envelope proteins and better binding of
V29A mutant to gp140CN54.
Figure 3. Competition between different VHH for binding toward recombinant envelope proteins. Competition matrix of VHH to
gp140UG37 (A) and gp140CN54 (B). The values shown represent the mean binding of envelope protein in presence of the competitor VHH. The effect of
competition is expressed in percent of positivity and marked mutual cross-competition (,30%) are shown by light grey cells and weak mutual cross-
competition (.75%) by dark grey cells.
doi:10.1371/journal.pone.0033298.g003
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binding to both envelope proteins was unchanged for most VHH
mutants. The exceptions were Y98A, Y99A and Y100cA mutants,
which bound worse to gp140UG37 and gp140CN54. Remarkably,
mutation of R100bA completely reduced binding of mutant to
gp140CN54, but not gp140UG37.
To verify the influence of the mutations on biological function of
the VHH, the neutralisation assays were performed against four
viruses (Table 4). The ZM233M.PB6 virus was the most resistant
and any mutation tested had an adverse effect on 2E7 potency. In
contrast Du156.12 virus was the most sensitive to all mutants except
Y98A mutant, which revealed decreased potency against all viruses.
Interestingly alanine substitution at position 29 slightly enhanced
the potency of 2E7 VHH against 96ZM651.02, 92UG37.A9 and
Du156.12, making this residue an interesting start point for future in
vitro maturation studies. This is in agreement with previously
observed enhancement of binding affinities.
Discussion
HIV-1 subtype C viruses have become predominant epidemic
strains in the world (http://www.unaids.org). The well described
broadly neutralizing antibodies of human origins b12, 2G12, 4E10
and 2F5 overall show limited neutralization of subtype C viruses
[12,13,63,64]. More recent, potent antibodies PG9, PG16 and
VRC01-03, have been selected from blood cells of HIV patients
[16,17,19,27]. Nonetheless selection of novel anti HIV-1 neutral-
izing antibodies is crucial for a better understanding of immune
responses to non-subtype B viruses. Further, it is important for the
development of better and cheaper microbicides, effective against
the most prevalent subtypes, as the recently tested tenofovir gel
only reached 39% protection [65].
In the current study, two llamas were immunized with a cocktail
of recombinant envelope proteins of HIV-1 subtype A (gp140UG37)
and B/C (gp140CN54) to select VHH against non-subtype B HIV-
1 using competitive elution. From the 280 clones tested, 30 clones
competed with b12. Sequence analysis revealed 17 different VHH
that were clustered into 7 families based on V-, D- and J- genes
used during their maturation. Our previous data, described by
Forsman et al. in 2008 [35] demonstrate that competition between
sCD4 and phages results in the release of a phage population
enriched in sCD4 competitors. Free gp140 is thought to sample
many conformations [66] and only CD4-bound conformation
Table 3. Neutralisation of the different viruses by the VHH and mAb b12.
IC50 in TZM-b1 cells (mg/mL)
Virus Subtype Tier 1C2 1F10 1E1 1B5 1H9 2D4 1E2 2E7 A12 C8 mAb b12
92UG37.A9 A nd 16 17 NNN NN16 NN N
MS208.A1 A 1 0.3 0.1 4.1 0.1 0.2 37 4.5 2.9 NN 0.6
T257-71 CRF02_AG 2 NNNNN NN45 NN N
T266-60 CRF02_AG 2 NNN5.5 8.7 N 15 9.0 NN N
T278-50 CRF02_AG 2 NNN10 11 NNNNN 25
T33-7 CRF02_AG 2 N 38 NNN NN38 NN N
MN B 1 6.7 17 NNN N39 17 0.2 4.5 0.1
IIIB B 1 NN39 6.4 5.6 NN10 0.02 0.3 0.04
JRFL B nd NNN48 42 NN36 NN 8.6
6535.3 B 2 NNN30 21 NN41 0.1 28 2.5
THRO4156.18 B 2 NNN21 24 NNN6.2 18 0.5
TRJO4551.58 B 2 NNN40 33 NNN16 NN
96ZM651.02 C 2 27 2.2 34 11 9 NN18 0.1 4.3 N
Du156.12 C 2 33 11 N 4.6 37 NN8.9 NN ,1.9
Du422.1 C 2 37 24 NNN NN22 NN ,1.9
ZM197M.PB7 C 2 8.2 5.2 39 16 8.8 NN38 6.0 24 7.4
ZM214M.PL15 C 2 6.0 4.3 N 32 NN N 22 NN ,1.9
ZM233M.PB6 C 2 0.2 0.2 N 48 NN 17 6.4 7.0 38 N
ZM109F.PB4 C 2 1.7 1.7 NNN NNN0.8 38 N
ZM135M.PL10a C 2 2.6 1.9 N 20 13 N 40 17 NN N
CAP45.2.00.G3 C 2 5.8 38 28 7.0 3.7 NN30 NN ,1.9
CH038.12 CRF07_BC 2 2.0 0.8 NNN NN13 NN ,1.9
CH064.20 CRF07_BC 2 4.5 1.5 N 15 22 32 N 20 NN N
CH091.9 CRF07_BC 2 14 4.5 N 8.2 38 50 N 36 NN N
CH110.2 CRF07_BC 2 6.3 2.6 NN40 N 18 16 NN N
CH181.12 CRF07_BC 2 2.5 0.8 17 5.9 7 50 NNNN ,1.9
VHH epitope group I I II II II III
Comparison of neutralization potencies of VHH and mAb b12 in TZM-b1 neutralisation assay against 26 viruses. IC50 values above 50 mg/mL are marked as N and IC50
values of A12, C8 and mAb b12 are cited from Forsman et al. [35].
doi:10.1371/journal.pone.0033298.t003
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assume that during selection, VHH could recognize different
envelope protein conformations, and subsequent elution with
sCD4, could release not only CD4bs binders, but also VHH that
interact with regions involved in transition to CD4-bound
conformation and therefore could reveal neutralisation activities.
The lack of crystal structures of envelope proteins in complex
with VHH prevents us to exactly localize VHH epitopes.
However, four sets of experimental data, i.e. binding to envelope
proteins (Table 1), sequences (Fig. 2), cross-competition data
(Figure 3) and neutralization data (Table 3), allowed us to
categorize the selected VHH into epitope groups. Moreover,
current knowledge of envelope protein with sCD4, b12 and F105
structures [68] and VHH interactions with mutated envelope
protein helped us to deduce the localisation of VHH epitopes. The
structural analysis studies have revealed that both sCD4 and b12
recognize non linear epitopes on the envelope protein, ranging
from amino acid 124 to 477, and that F105 binds to a different site
than b12 [2,69]. This information has been applied by the group
of Peter Kwong to construct mutant envelope proteins, in which
the bridging sheet was tethered to the inner domain [21]. We used
both mutated (gp120Ds2) and wild type gp120YU2 envelope
proteins for VHH characterisation. Similarly to most of the
antibodies that target the site of CD4 binding [2] the previously
selected high affinity VHH A12 and D7 [35] most likely recognize
the cavity under the bridging sheets as they bound to gp120YU2,
but not to gp120Ds2.
More recent studies show that VHH A12 and the related VHH
D7 [35,70] most likely bind to an epitope equal or closely related
to the epitope recognized by F105 (Chen, in preparation). Since
F105 is not a broad neutralizing antibody, this epitope will most
likely not yield broad VHH either and thus there is a need for
VHH that recognize other epitopes. From the VHH selected in
this study, the VHH of group I (represented by 1F10 and 1C2) did
not bind to subtype B envelope proteins, showed different
competition and neutralization patterns than VHH of groups II
and III and therefore they may bind to B20/B21, which forms a
loop between the cavity and the outer domain. The VHH
belonging to group II (1B5, 1H9, 1E1) most likely recognize the
outer domain contact site for CD4 of the envelope protein [2],
since these VHH interacted with both gp120Ds2 and gp120YU2.
However, in contrast to b12, VHH 1B5 recognized a larger
number of viruses including non B viruses and neutralized in total
18 out of 26 viruses.
Based on these considerations and the 3D structures of envelope
proteins we propose that the three major groups of anti-HIV
VHH bind to the envelope protein in the cavity below the bridging
sheets (A12/D7), the bridging sheet themselves (1F10) and the
outer domain (1B5). VHH 2E7, representing group III, bound
slightly to gp120IIIB, but not to gp120YU2 nor to gp120Ds2 and had
the broadest neutralisation spectrum of HIV-1 subtypes (21 out of
26) of any of the other CD4bs targeting antibodies derived from
immunizations. The epitope recognized by VHH 2E7 differs from
the antigenic determinants of the 1B5 group as is shown by
competition experiments and the various spectra of viruses
neutralized by group II and III. Cross-competition between 2E7
and 1E2 or 1C12 VHH probably resulted from alteration of the
antigenic determinant conformation by the competing VHH or
steric occlusion. To further map the exact location where the
VHH bind to the envelope protein, competition assays can be
performed with more mAbs of known specificity. Also their
binding to two additional Yu-2 mutants, D368R which is not
bound by sCD4 or CD4bs mAbs, or I420R which is no longer
bound by CD4i specific mAbs, can be tested [18]. The large
breadth of VHH 2E7 and 1B5 makes them interesting candidates
for further studies. For that reason we carried out a restricted
number of mutations on basis of the maturation analysis and this
provided us with both an improved neutralising 2E7 VHH variant
and insight, which amino acids of CDR1 and CDR3 take part in
envelope protein binding.
Although the VHH epitopes still remain to be precisely
localized with biophysical methods, our data strongly suggest that
the neutralising VHH recognized various epitopes. In vitro
maturation of 2E7 and 1B5 and construction of biparatopic
VHH [71], in particular biparatopic VHH of group I and II or II
and III, might broaden virus cross-neutralization and enhance the
VHH potency. The effect of bivalency was recently described with
a molecule that combined the binding domains of sCD4 and 17b
with a 35 amino acid linker. This construct neutralized all 47
strains tested coming from clade A, B, C, D, F, A/E and A/G,
90% with an IC50 below 4 mg/ml [72].
The evidence that cell-to-cell transfer may be a major factor in
spreading the HIV-1 [28,73] and the fact that VHH are small
enough to operate in the viral synapsis may increase the potential
of anti-HIV-1 VHH as functional ingredient in microbicides just
as their generally high stability [74]. As microbicides are generally
tested on simian-human immunodeficiency virus (SHIV) a small
scale assay was performed to evaluate that. 1B5 and 2E7 were
active against type B SHIV, 1B5 and 1F10 against type C SHIV
(to be published). Finally, the new VHH recognizing three
different areas of the CD4bs may provide useful insight into
vaccine development.
Supporting Information
Figure S1 Binding of CD4 and B12 against recombinant
gp140. Binding of 3 mg/mL sCD4 (solid line) and 100 ng/mL
b12 antibody (dashed line) to gp140UG37 (black triangle) or
gp140CN54 (black square) directly coated.
(TIF)
Table 4. Neutralisation potencies of wild type VHH 2E7 and mutated variants in TZM-b1 neutralisation assay.
IC50 in TZM-b1 cells (mg/ml)
Virus Subtype Tier Wild type V29A Y98A R100bA Y100cA Y102A
92UG37.A9 A Nd 16 9 28 16 13 12
96ZM651.02 C 2 18 9 23 20 28 14
Du156.12 C 2 9 4 11 5 6 3
ZM233M.PB6 C 2 6 14 45 33 28 23
Comparison of neutralization potencies of VHH 2E7 wild type and 5 mutants against a panel of 4 viruses. IC50 values are given in mg/mL. Not done is marked as Nd.
doi:10.1371/journal.pone.0033298.t004
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33298Figure S2 Binding of VHH to various recombinant
envelope proteins. Binding of VHH to gp120Ds2 (black square),
gp120 IIIB (dark grey square), gp140CN54 (light grey square),
gp140UG37 (white square) and gp120YU2 (dashed). Binding was
tested in an ELISA setup and expressed by means of absorbance
(A490) with subtracted background.
(TIF)
Figure S3 Inhibition of the binding of the recombinant
envelope proteins toward b12 by the VHH. Binding of
HIV-1 envelope proteins gp120 IIIB (dark grey square). gp140CN54
(light grey square). gp140UG37 (white square) in complex with
VHH to immobilized mAb b12. Data are expressed as percent of
positivity calculated by equation 100*((A490sample2A490 min)/
(A490max2A490 min)) where A490 min is a A490 of sample without
VHH and without gp for particular gp and day of experiment; and
A490max is A490 of samples without VHH for particular envelope
protein and day of experiment.
(TIF)
Table S1 Binding of 2E7 wild type and mutants to
recombinant envelope proteins. Binding affinities of VHH
2E7 and a panel of its modified variants to HIV-1 envelope
proteins gp140UG37 and gp140CN54 as measured by ELISA.
a
Binding affinities were calculated as the antibodies concentration
at half-maximal binding.
b Key: n.b., no binding was determined.
(XLS)
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